Here are four takeaways:
1. Nuvectra is a medical device company developing a neurostimulation technology platform for chronic pain treatment.
2. The company’s main product, Algovita, is a spinal cord stimulation system.
3. The funds will help Nuvectra introduce Algovita to the U.S. market.
4. The credit facility includes a $40 million senior secured term loan and a $5 million line of credit.
More articles on devices:
Amedica, SI-BONE, Stryker & more: 14 key notes
Stryker completes CareFusion’s VCF acquisition: 5 takeaways
FDA panel finds Cartiva SCI safe, effective: 3 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
